The launch of ExL's BD&L Summit for Life Sciences was so successful last year that the 2nd BD&L Summit returns to serve as an open forum for cross-functional business development teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements and M&A deals. This year, the conference will go one step further and provide two tracks dedicated to the Legal/Transactions and Business Development areas. 

WHAT TO EXPECT AT THE 2ND BD&L SUMMIT

• New tracked program offers a selection of sessions so you can optimize your learning experience and focus on topics important to you and your company
• Identify key business goals and map out a clear strategy for potential M&As with respect to tax inversion, consolidation, divestitures, and narrowing strategic focus to maximize portfolio value
• Understand how to conduct a comprehensive intellectual property due diligence investigation, and how it can alter the strategy for your deal 
• Gain valuable insight into the impact company culture can have on the success of integrating the workforce post-merger or acquisition 

WHO SHOULD ATTEND

This conference is designed for representatives from pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas: 

• Business Development/Corporate development
• Mergers and Acquisitions
• Licensing
• Strategic Alliance/Alliance Management
• Intellectual Property and Patent Counsel
• Search and Evaluation
• Due Diligence
• External Innovation
• Transactions
• Portfolio Management
• Scientific Assessment
• General Counsel/Corporate Counsel
• Legal and Regulatory Compliance
• Regulatory Affairs
• Research and Development
• Clinical Medicine
• Clinical Operations
• Life Cycle Management

This conference is also of interest to:

• Investment Banks
• Private Equity Firms
• Venture Capitalists
• Data Room Providers
• Due Diligence Consultants
• Law Firms
• Clinical Affairs and CRO Partners
• Regulatory Affairs and Compliance Partners